Clinical effect of bortezomib and thalidomide on multiple myeloma patients and their influence on coagulation function

Objective To compare the clinical efficacy of bortezomib and thalidomide on multiple myeloma (MM) and analyze the influence of the two chemotherapy on coagulation function.Method Forty patients with multiple myeloma were divided into bortezomib group (n=20) and thalidomide group (n=20) according to different chemotherapy regimens.Both groups were treated with epirubicin and dexamethasone,the patients receiving bortezomib were additionally given intravenous injection of bortezomib,while those in thalidomide group were administered with thalidomide.The clinical efficacy,coagulation function before and after chemotherapy,and adverse reactions after chemotherapy were compared between the two groups.Result The remission and incidence of adverse reactions in two group were consistent, with no statistically significant differences observed (P>0.05).After chemotherapy,the thrombin time (TT),prothrombin time (PT),activated partial thromboplastin time (APTT),fibrinogen (FIB),D-dimer level and platelet aggregation rate in bortezomib group and thalidomide group were decreased significantly compared with those before treatment,and thalidomide group,the difference was statistically significant (P<0.05).Conclusion The clinical effect of bortezomib was generally comparable to that of thalidomide for multiple myeloma,but bortezomib scheme is beneficial to improving the coagulation function and reduce the possibility of thrombosis.